•  
  •  
image-723919-Mission_AD_logo.jpg
                       


       TRAILBLAZER-ALZ

              

          I5T-MC-AACG


What follows is a brief summary of the Lilly Phase 2 TRAILBLAZER trial of combination therapy using a beta-secretase inhibitor + an anti-amyloid vaccine designed to slow down the progression of disease for individuals with MCI or mild dementia due to Alzheimer's. 

  • Drug administration -- daily oral and/or monthly IV  

  • Age range -- 50-85

  • MMSE range -- 24-30

  • Study Duration -- 24 mos.

  • Target population -- Early Alzheimer's (MCI, very mild dementia). Amyloid PET or CSF positive at screening                                                                        

  • Mechanism of action --  blocks formation of active beta amyloid protein (BACE inhibition) + removes existing amyloid beta block

  • Randomization split --

  • Type(s) of imaging -- brain MRI, CT, amyloid PET, Tau PET


For more details on this specific trial, visit:


ClinicalTrials.gov
                                                                         
             A service of the U.S. National Institutes of Health

Donald S. Marks, M.D., P.C. -- 45 Resnik Road, Suite 205 -- Plymouth, MA, 02360

Tel: (508) 746-5060   Fax: (508) 746-8060